Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Farther Finance Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD
04:07am, Friday, 17'th Apr 2026
Farther Finance Advisors LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 43.9% during the undefined quarter, according to the company in its most recent filing with the Secu
Gilead Sciences, Inc. $GILD Stock Holdings Lowered by Assetmark Inc.
03:28am, Friday, 17'th Apr 2026
Assetmark Inc. lowered its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 7.3% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor own
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Thursday, 16'th Apr 2026
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bingham Private Wealth LLC Invests $1.42 Million in Gilead Sciences, Inc. $GILD
03:35am, Wednesday, 15'th Apr 2026
Bingham Private Wealth LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commis
Here's Why Gilead Sciences (GILD) Gained But Lagged the Market Today
07:01pm, Tuesday, 14'th Apr 2026
In the most recent trading session, Gilead Sciences (GILD) closed at $140.45, indicating a +1.02% shift from the previous trading day.
PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
12:00pm, Tuesday, 14'th Apr 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #EndHIV--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. State Department, the United States President's Emergency Plan for AIDS Relief (PEPFA
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:56am, Tuesday, 14'th Apr 2026
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing
09:57pm, Monday, 13'th Apr 2026
SAN FRANCISCO--(BUSINESS WIRE)-- #AHFcares--Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing.
Altfest L J & Co. Inc. Sells 4,944 Shares of Gilead Sciences, Inc. $GILD
03:46am, Monday, 13'th Apr 2026
Altfest L J and Co. Inc. reduced its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 72.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
01:06pm, Friday, 10'th Apr 2026
Kymera Therapeutics secures $45M as Gilead licenses KT-200, advancing a novel CDK2 degrader with potential in breast cancer and solid tumors.
AHF Slams Gilead for Role in Florida AIDS Drug Crisis
01:01pm, Friday, 10'th Apr 2026
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #AHFcares--AHF Slams Gilead for Role in Florida AIDS Drug Crisis.
Gilead Expands Oncology Pipeline With $5B Tubulis Deal
01:11pm, Thursday, 09'th Apr 2026
Gilead's $5B Tubulis deal expands its ADC pipeline, boosting oncology ambitions as the company accelerates strategic acquisitions beyond HIV.
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
08:30am, Thursday, 09'th Apr 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilea
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead's First Option Target Exercise
07:30am, Thursday, 09'th Apr 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., a clinical-stage biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announ
Gilead Sciences Details Tubulis, Ouro, Arcellx Deals as Pipeline Catalyst, 2026 Updates Loom
03:38am, Thursday, 09'th Apr 2026
Gilead Sciences (NASDAQ: GILD) executives on Tuesday outlined the company's rationale for three recently announced transactions-its proposed acquisitions of Tubulis, Ouro Medicines, and Arcellx-framin
